Lexeo is participating in two investor conferences this month, find more information on our website: https://lnkd.in/g38cBftQ
Lexeo Therapeutics
Biotechnology Research
New York, New York 13,191 followers
Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
About us
Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.
- Website
-
http://www.lexeotx.com
External link for Lexeo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
345 Park Avenue South
6th Floor
New York, New York 10010, US
Employees at Lexeo Therapeutics
Updates
-
Lexeo announced financial results and operational updates for the third quarter of 2025 this morning. Read the full release: https://lnkd.in/eDtWyDMC
-
-
Lexeo is heading to New Orleans for #AHA25! Join us for a symposium with Drs. Chet Villa and Esteso Paul, moderated by Dr. Aravindhan Veerapandiyan on Saturday, Nov. 8 from 1:45–2:30 PM CT in Heart Theater I. We look forward to connecting with you onsite!
-
-
Our CEO, Nolan Townsend, recently joined Ayesha Rashid of the Xtalks Life Science Podcast to discuss how Lexeo is working to shape the future of genetic medicines. Listen to the episode here: https://lnkd.in/ehHJ6pAj
-
Lexeo Therapeutics reposted this
We've just announced a public offering and concurrent private placement with gross proceeds of approximately $135 million. Read the press release on our website: https://lnkd.in/eTfyqz6t
-
-
We've just announced a public offering and concurrent private placement with gross proceeds of approximately $135 million. Read the press release on our website: https://lnkd.in/eTfyqz6t
-
-
Lexeo was proud to sponsor and attend the Friedreich's Ataxia Research Alliance (FARA) Energy Ball in Tampa, joining hundreds of advocates, families and researchers united in the fight against FA. Many of our colleagues, from all functions, showed up with heart and purpose to share their passion for advancing genetic medicine research and their commitment to the FA community. We are grateful to this community for their partnership, candor and trust, and we’re hopeful for the future. Learn more about Lexeo’s research in FA: https://lnkd.in/exYWF9U7 #Friedreichataxia #genetherapy
-
-
Lexeo is participating in two investor conferences in October, find more information on the Events section of our website: https://lnkd.in/g38cBftQ
-
-
This morning, we announced progress in FDA discussions on an Accelerated Approval pathway for LX2006 for the treatment of Friedreich ataxia cardiomyopathy, alongside positive interim clinical data from ongoing Phase I/II clinical trials. Read the full release: https://lnkd.in/eZAT6dRY #Friedreichataxia #cardiomyopathy #FA #genetherapy
-
-
Our CEO, Nolan Townsend, recently joined The BioHub Podcast to share Lexeo's story and evolution to focusing on cardiac genetic medicine today. Listen on your favorite platform. YouTube: https://lnkd.in/eVzE9PkY Apple Podcasts: https://lnkd.in/e-i-8EUa Spotify: https://lnkd.in/eCcUhi4G
-